PHOspholamban RElated CArdiomyopathy STudy - Intervention

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Phospholamban R14del Mutation-related Cardiomyopathy
Interventions
DRUG

Eplerenone

eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day

Trial Locations (4)

1105 AZ

AMC, Amsterdam

8600BA

Antonius ziekenhuis Sneek, Sneek

9700RB

UMCG, Groningen

3584 CX

UMCU, Utrecht

All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

The Interuniversity Cardiology Institute of the Netherlands

OTHER_GOV

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Netherlands: CVON, CardioVascular Research Netherlands

UNKNOWN

lead

M.p. van den Berg, MD, PhD, professor in Cardiology

OTHER

NCT01857856 - PHOspholamban RElated CArdiomyopathy STudy - Intervention | Biotech Hunter | Biotech Hunter